American Diabetes Association Scientific Sessions

SAN DIEGO — In the DEVOTE cardiovascular outcomes trial, insulin degludec was noninferior to insulin glargine for the primary endpoint of major adverse cardiovascular events and was associated with significant reductions in severe hypoglycemia among high-risk patients with type 2 diabetes.

The American Diabetes Association 77th Scientific Sessions recently wrapped in San Diego. Topics discussed included lowering cardiovascular risks in patients with type 2 diabetes, improving diabetes-related depression, managing and preventing diabetes during pregnancy and more.

SAN DIEGO — A hybrid-closed loop insulin control system used in children with type 1 diabetes was safe for both overall and overnight control and resulted in no severe hypoglycemic episodes, according to a speaker here.

SAN DIEGO — Self-monitoring of blood glucose with or without tailored messages did not significantly improve glycemic control compared with no self-monitoring of blood glucose in adults with type 2 diabetes.

SAN DIEGO — Adults with type 2 diabetes assigned to once-daily oral insulin achieve similar HbA1c and fasting plasma glucose levels compared with those assigned to once-daily subcutaneous insulin, according to a presenter here.

SAN DIEGO — Middle-aged adults with long-standing type 1 diabetes at high risk for cardiovascular disease who added metformin to insulin therapy for 3 years saw reductions in body weight, LDL cholesterol and atherosclerosis progression vs. those assigned placebo, according to a speaker here.

SAN DIEGO — In adults with two or more antibodies predicting the development of type 1 diabetes, treatment with daily oral insulin therapy did not prevent development of the disease, but a small subset experienced a 31-month delay in clinical diabetes development, according to a speaker here.

SAN DIEGO — A single dose of an investigational agent that blocks glucagon receptors can lower the amount of insulin needed and improve glucose levels without increased hypoglycemia in adults with type 1 diabetes, according to a presenter here.

SAN DIEGO — Moderate to severe hypoglycemic episodes in adults with type 1 diabetes may effectively be treated with nasal glucagon, and caregivers can safely administer the medication, according to findings presented here.

SAN DIEGO — Incorporating an exercise detection function into a dual-hormone closed-loop glucose control system may help users with type 1 diabetes avoid exercise-induced hypoglycemia.